Trial Profile
A Phase I/II Study of S-1 in Combination with Sorafenib in Patients with Metastatic Renal Cell Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 20 May 2016
Price :
$35
*
At a glance
- Drugs Gimeracil/oteracil/tegafur (Primary) ; Sorafenib
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Taiho Pharmaceutical Company
- 28 Apr 2014 New trial record
- 01 Feb 2014 Phase II results presented at the 2014 Genitourinary Cancers Symposium.